Heart failure & cardiomyopathies
Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial
Study context
- Population
- Patients with HF with reduced ejection fraction (HFrEF) (LVEF ≤40%) with smartphone access and English proficiency
- Participants
- 178 patients
- Comparison
- Remote digital guideline-directed medical therapy (GDMT) optimisation intervention vs usual care
- Primary endpoint
- Change from baseline in GDMT by HF Collaboratory Score (HFC; use and dose of prescribed GDMT)
- Follow-up
- 6 months
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
Baseline characteristics · enrolment
- Age, median (Q1-Q3), years
- 66.4 (56.1-73.1)
- Female
- 38.8%
- Hypertension
- 71.3%
- CAD
- 45.5%
- AF/flutter
- 31.5%
- T2DM
- 28.1%
- HFC score, median (Q1-Q3)
- 5 (4-6)
- Evidence-based beta blocker
- 84.8%
- ARNI
- 48.9%
- MRA
- 48.9%
- SGLT2 inhibitor
- 47.2%
Original publication
Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial. Am Heart J. Published 3 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →